Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI-505 in smoldering multiple myeloma
NCT01838369Phase 2Terminated
- Sponsor
- BioInvent International
- Start
- Mar 2013
- Primary completion
- Dec 2014
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bersanlimab in smoldering multiple myeloma (SMM), sponsored by BioInvent International. Started Mar 2013; status: terminated.
02
Drugs
bersanlimab
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT01838369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01838369.